Depressive Disorders - LATAM | Statista Market Forecast

Revenue in the Depressive Disorders market is projected to reach US$1.52bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of -0.55%, resulting in a market volume of US$1.48bn by 2029.
In global comparison, most revenue will be generated United States (US$6.26bn in 2024).
In relation to total population figures, per person revenues of US$53.89 are generated in 2024.

Depressive disorders are a common type of mental illness. Symptoms include depressive moods such as feeling sad, low concentration, low self-worth, loss of interest in activities, and, in some cases, thoughts of suicide. Common treatments for depressive disorders include psychological treatments such as psychotherapy, behavioral therapy, and antidepressant medication.

The Depressive Disorders market in the Mental Health market represents the market for antidepressant drug sales. Different types of antidepressants are usually prescribed for the treatment of mild to serious cases of depression, e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitor (SNRIs), serotonin modulators, as well as tricyclic and tetracyclic antidepressants.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Novartis AG, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Patheon Inc, and Sandoz Inc.

Antidepressant drugs
Selective serotonin reuptake inhibitors (SSRIs)
Serotonin norepinephrine reuptake inhibitor (SNRIs)
Serotonin modulators
Tricyclic and tetracyclic antidepressants

Psychotherapy
Mood stabilizers
Anti-anxiety and stimulant medications
Behavioral therapy

The Depressive Disorders market in LATAM has been experiencing significant growth in recent years. Customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors have all contributed to this development.Customer preferences in the Depressive Disorders market in LATAM have shifted towards a greater emphasis on mental health and well-being. As awareness about mental health issues increases, more people are seeking treatment for depressive disorders. This has led to a higher demand for medications and therapies that can effectively manage these conditions.Trends in the market indicate that there is a growing acceptance and understanding of depressive disorders in LATAM. Governments and healthcare organizations have implemented initiatives to raise awareness about mental health and reduce the stigma associated with mental illnesses. This has resulted in increased access to mental health services and improved treatment options for individuals suffering from depressive disorders.Local special circumstances in LATAM have also contributed to the growth of the Depressive Disorders market. The region has a high prevalence of depressive disorders, with a significant portion of the population experiencing symptoms of depression. This has created a large customer base for pharmaceutical companies and healthcare providers to cater to.Underlying macroeconomic factors have played a role in the development of the Depressive Disorders market in LATAM. Economic growth in the region has led to an increase in disposable income, allowing individuals to afford the necessary treatments and medications for depressive disorders. Additionally, improvements in healthcare infrastructure and insurance coverage have made mental health services more accessible to a larger segment of the population.In conclusion, the Depressive Disorders market in LATAM is developing due to changing customer preferences, increasing awareness and acceptance of mental health issues, local special circumstances, and underlying macroeconomic factors. As the region continues to prioritize mental health and well-being, it is expected that the market for depressive disorders will continue to grow in the coming years.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.